Initiation of and persistence with P2Y12 inhibitors in patients with myocardial infarction according to revascularization strategy: a nationwide study
Publikation: Bidrag til tidsskrift › Tidsskriftartikel › Forskning › fagfællebedømt
Standard
Initiation of and persistence with P2Y12 inhibitors in patients with myocardial infarction according to revascularization strategy : a nationwide study. / Tajchman, Daniel H; Nabi, Hafsah; Aslam, Mohsin; Butt, Jawad H; Grove, Erik L.; Engstrøm, Thomas; Holmvang, Lene; Fosbøl, Emil L.; Køber, Lars; Sørensen, Rikke.
I: European Heart Journal: Acute Cardiovascular Care, Bind 10, Nr. 7, 2021, s. 774-786.Publikation: Bidrag til tidsskrift › Tidsskriftartikel › Forskning › fagfællebedømt
Harvard
APA
Vancouver
Author
Bibtex
}
RIS
TY - JOUR
T1 - Initiation of and persistence with P2Y12 inhibitors in patients with myocardial infarction according to revascularization strategy
T2 - a nationwide study
AU - Tajchman, Daniel H
AU - Nabi, Hafsah
AU - Aslam, Mohsin
AU - Butt, Jawad H
AU - Grove, Erik L.
AU - Engstrøm, Thomas
AU - Holmvang, Lene
AU - Fosbøl, Emil L.
AU - Køber, Lars
AU - Sørensen, Rikke
PY - 2021
Y1 - 2021
N2 - Background We aimed to analyse initiation of and persistence with P2Y(12) inhibitors after first-time myocardial infarction (MI).Methods and results Using Danish nationwide registries, we identified patients >= 30years with first-time MI during 1 January 2005-30 June 2016 and subsequent prescriptions of P2Y(12) inhibitors. Independent factors related to initiation of and persistence with P2Y(12) inhibitors were analysed by multivariable logistic regression and a Cox proportional hazards model. Patients were stratified by revascularization strategy: percutaneous coronary intervention (PCI), coronary artery bypass graft (CABG), or medical therapy alone (MTA). Overall, 79597 MI patients were included with 39172 undergoing PCI, 2619 CABG, and 16640 MTA, showing initiation of P2Y(12) inhibitors of 93.4%, 49.0%, and 51.5%, respectively. Congestive heart failure, cerebrovascular disease, cardiac dysrhythmias, renal failure, previous bleeding, and oral anticoagulants were associated with less initiation of P2Y(12) inhibitors. Female sex was associated with less initiation of P2Y(12) inhibitors following MTA. MTA, coronary angiography, cerebrovascular disease, diabetes with complications, previous bleeding, antidiabetics, and ticagrelor as P2Y(12) inhibitor were associated with non-persistence, whereas female sex, advanced age, and concomitant pharmacotherapy with angiotensin-converting enzyme inhibitors, beta-blockers, statins, oral anticoagulants, and aspirin were associated with high persistence.Conclusion Initiation of P2Y(12) inhibitors in PCI-treated MI patients was high in contrast to those treated with CABG or MTA and patients with certain comorbidities. Further studies on the benefit-risk ratio of P2Y(12) inhibitors in CABG-treated or MTA-treated patients and patients with comorbidities after first-time MI are warranted, as is focus on persistence among patients receiving MTA, patients with comorbidities, and users of ticagrelor.
AB - Background We aimed to analyse initiation of and persistence with P2Y(12) inhibitors after first-time myocardial infarction (MI).Methods and results Using Danish nationwide registries, we identified patients >= 30years with first-time MI during 1 January 2005-30 June 2016 and subsequent prescriptions of P2Y(12) inhibitors. Independent factors related to initiation of and persistence with P2Y(12) inhibitors were analysed by multivariable logistic regression and a Cox proportional hazards model. Patients were stratified by revascularization strategy: percutaneous coronary intervention (PCI), coronary artery bypass graft (CABG), or medical therapy alone (MTA). Overall, 79597 MI patients were included with 39172 undergoing PCI, 2619 CABG, and 16640 MTA, showing initiation of P2Y(12) inhibitors of 93.4%, 49.0%, and 51.5%, respectively. Congestive heart failure, cerebrovascular disease, cardiac dysrhythmias, renal failure, previous bleeding, and oral anticoagulants were associated with less initiation of P2Y(12) inhibitors. Female sex was associated with less initiation of P2Y(12) inhibitors following MTA. MTA, coronary angiography, cerebrovascular disease, diabetes with complications, previous bleeding, antidiabetics, and ticagrelor as P2Y(12) inhibitor were associated with non-persistence, whereas female sex, advanced age, and concomitant pharmacotherapy with angiotensin-converting enzyme inhibitors, beta-blockers, statins, oral anticoagulants, and aspirin were associated with high persistence.Conclusion Initiation of P2Y(12) inhibitors in PCI-treated MI patients was high in contrast to those treated with CABG or MTA and patients with certain comorbidities. Further studies on the benefit-risk ratio of P2Y(12) inhibitors in CABG-treated or MTA-treated patients and patients with comorbidities after first-time MI are warranted, as is focus on persistence among patients receiving MTA, patients with comorbidities, and users of ticagrelor.
KW - Platelet aggregation inhibitors
KW - Clopidogrel
KW - Ticagrelor
KW - Prasugrel
KW - Percutaneous coronary intervention
KW - Coronary artery bypass
KW - DUAL ANTIPLATELET THERAPY
KW - ACUTE CORONARY SYNDROMES
KW - ST-SEGMENT ELEVATION
KW - CLOPIDOGREL TREATMENT
KW - ASPIRIN
KW - MANAGEMENT
KW - MORTALITY
KW - RISK
KW - VALIDATION
KW - TICAGRELOR
U2 - 10.1093/ehjacc/zuab043
DO - 10.1093/ehjacc/zuab043
M3 - Journal article
C2 - 34570197
VL - 10
SP - 774
EP - 786
JO - European Heart Journal: Acute Cardiovascular Care
JF - European Heart Journal: Acute Cardiovascular Care
SN - 2048-8726
IS - 7
ER -
ID: 302819266